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Trastuzumab (Herceptin®), a humanized anti-ErbB2
antibody is a specific targeted therapy against ErbB2
positive tumors, with a history of both success and a
high rate of therapy resistance. Another humanized anti-
body, pertuzumab (Perjeta®) inhibits ErbB2 heterodi-
merization. While these antibodies have been developed
based on the in vitro direct cellular effect of their
mouse parent antibodies, there is the possibility that
their in vivo mechanism of action roots rather in anti-
body dependent cellular cytotoxicity (ADCC) exerted by
natural killer (NK) cells. Our goal was to ascertain the
extent of contribution of the direct cellular effect of the
antibodies and that of the in vivo evoked ADCC to
tumor growth inhibition. We generated the F(ab’)2 frag-
ments of the antibodies lacking the Fc part, that have
the ability to generate direct cellular effects, but lack the
ADCC component. Affinity and lack of Fc fragment on
F(ab’)2-s were tested with immunofluorescence in flow
cytometry. In vitro EC50 was assessed with an MTT
based assay. The effect on proliferation of in vitro sensi-
tive BT-474 and resistant JIMT-1 cell lines, both ErbB2
positive, was not affected by the removal of the Fc
region. Based on the EC50 values determined as single
agents on BT-474 cells, isoboles for a range of combina-
tion were also measured for both the whole antibodies
and the F(ab’)2 fragments and no co-operativity was
found. Non-radioactive in vitro ADCC assay on JIMT-
1cell line was optimized with CD16.176V.NK-92 high
affinity natural killer cell line. Intact antibodies mediated
in vitro ADCC-based killing, while F(ab’)2 fragments did
not. Formation of immunological synapses was verified
by confocal microscopy. NK-92 cells were able to form
synapses upon recognition of whole antibodies by their
high affinity FcgRIII, while owed to the lack of Fc
region, synapse formation did not occur with F(ab’)2-s.
For in vivo ADCC study, JIMT-1 cells were inoculated
s.c. in severe combined immunodeficiency mice. The
whole antibodies were able to inhibit tumor growth, but
their F(ab’)2 fragments were ineffective. Combination of
the whole antibodies showed a great degree of syner-
gism in vivo, which possibly indicates synergism of two
antibodies on the same target protein recruiting FcgRIII
receptors and a consequentially better binding and acti-
vation of NK cells.
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